Eli Lilly and Company (LLY)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 00:36 UTC · Figures derived from the full chain (4,252 contracts, 19 expirations) · IV own-history percentile appears after 60 recorded days (4 so far)
Expected move — Sep 18, 2026 (15 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±5.0% (range 1,101.20–1,217.90) by Sep 18, 2026. ATM straddle: 58.35 @ strike 1,160 · ATM IV: 31.0%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 1,043.59 | -10% | 95.0% | 5.0% |
| 1,101.57 | -5% | 78.4% | 21.6% |
| 1,159.55 | +0% | 48.7% | 51.3% |
| 1,217.53 | +5% | 20.9% | 79.1% |
| 1,275.50 | +10% | 6.1% | 93.9% |
Model-estimated probabilities of finishing above/below each level at expiration — estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Sep 18, 2026 · lognormal model, zero drift — an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Sep 04, 2026 | 1 | ±1.4% | 33.7% | 35.3K |
| Sep 11, 2026 | 8 | ±3.2% | 26.8% | 19.3K |
| Sep 18, 2026 | 15 | ±5.0% | 31.0% | 75.1K |
| Sep 25, 2026 | 22 | ±6.0% | 30.7% | 14.5K |
| Oct 02, 2026 | 29 | ±7.0% | 31.1% | 11.0K |
| Oct 09, 2026 | 36 | ±7.9% | 31.6% | 2,752 |
| Oct 16, 2026 | 43 | ±8.6% | 31.4% | 32.9K |
| Oct 23, 2026 | 50 | ±9.3% | 31.4% | 0 |
| Nov 20, 2026 | 78 | ±13.5% | 36.6% | 13.9K |
| Dec 18, 2026 | 106 | ±15.7% | 36.6% | 34.4K |
| Jan 15, 2027 | 134 | ±17.1% | 35.4% | 54.1K |
| Mar 19, 2027 | 197 | ±21.6% | 36.9% | 13.0K |
Open interest by strike — Sep 18
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 1,300 C · 5,0641,000 P · 4,6811,620 C · 4,1231,400 C · 4,0391,320 C · 3,769
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Track record
Full history →Every trading day we record what the options market is pricing for each expiration — before the outcome is known. Once expirations start resolving, this section compares expected versus actual, and the record is never rewritten. Recording since Aug 31, 2026.
Past earnings reactions
Avg |reaction| 6.3% · median 4.7% (20 reports) — two-session close-to-close window; definition
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HE
Healthcare · Drug Manufacturers - General · NYSE · Profile: Financial Modeling Prep
LLY news
All news →Salesforce Raised Guidance Again. Now It Has to Deliver the Revenue Acceleration
Yahoo Finance · Sep 03, 20:03 UTC ↗Wall Street is betting on Fed Chair Kevin Warsh to keep a manic bond market from unraveling
The market “needs stability and trust” as a deluge of corporate bond supply is expected in the coming months.
MarketWatch · Sep 03, 19:09 UTC ↗Is the stock market open on Labor Day? Does the post office deliver mail?
Here’s how trading hours and other services are affected by the Labor Day holiday on Monday, Sept. 7.
MarketWatch · Sep 03, 18:30 UTC ↗Average 401(k), IRA balances hit record highs — but more workers are raiding their accounts, Fidelity says
Retirement account balances rose in the second quarter amid market gains, according to Fidelity. At the same time, more savers tapped their…
CNBC · Sep 03, 15:42 UTC ↗Wall Street is betting on Fed Chair Kevin Warsh to keep a manic bond market from unraveling
The market “needs stability and trust” as a deluge of corporate bond supply is expected in the coming months.
Market Watch · Sep 03, 15:09 UTC ↗Related securities — Healthcare
MRNA · IV 75.2%HIMS · IV 67.1%PFE · IV 19.9%UNH · IV 25.0%MDT · IV 25.6%JNJ · IV 21.8%